Breast carcinoma is the most common female cancer with considerable metastatic potential. Discovery of new therapeutic approaches for treatment of metastatic breast cancer is still needed. Here, we reported our finding with niclosamide, an FDA approved anthelmintic drug. The potency of niclosamide on breast cancer was assessed in vitro and in vivo. In this investigation, we found that niclosamide showed a dramatic growth inhibition against breast cancer cell lines and induced apoptosis of 4T1 cells in a dose-dependent manner. Further, Western blot analysis demonstrated the occurrence of its apoptosis was associated with activation of Cleaved caspases-3, down-regulation of Bcl-2, Mcl-1 and Survivin. Moreover, niclosamide blocked breast cancer cells migration and invasion, and the reduction of phosphorylated STAT3Tyr705, phosphorylated FAKTyr925 and phosphorylated SrcTyr416 were also observed. Furthermore, in our animal experiments, intraperitoneal administration of 20 mg/kg/d niclosamide suppressed 4T1 tumor growth without detectable toxicity. Histological and immunohistochemical analyses revealed a decrease in Ki67-positive cells, VEGF-positive cells and microvessel density (MVD) and an increase in Cleaved caspase-3-positive cells upon niclosamide. Notably, niclosamide reduced the number of myeloid-derived suppressor cells (MDSCs) in tumor tissues and blocked formation of pulmonary metastases. Taken together, these results demonstrated that niclosamide may be a promising candidate for breast cancer.
References
[1]
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.
[2]
DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61: 408–418.
[3]
Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HAT (2013) Progesterone metabolites regulate induction, growth and suppression of estrogen-and progesterone receptor-negative human breast cell tumors. Breast Cancer Res 15: R38.
[4]
Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, et al. (2006) Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 12: S54–S69.
[5]
Liu MR, Casimiro MC, Wang CG, Shirley LA, Jiao XM, et al. (2009) p21CIP1 attenuates Ras-and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A 106: 19035–19039.
[6]
Ottenhoff-Kalff AE, Rijksen G, Van Beurden E, Hennipman A, Michels A, et al. (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52: 4773–4778.
[7]
Brennan K, Brown AM (2003) Is there a role for Notch signalling in human breast cancer? Breast Cancer Res 5: 69–75.
[8]
Cai JC, Guan HY, Fang LS, Yang Y, Zhu X, et al. (2013) MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest 123: 566–579.
[9]
Harrison H, Sim？es BM, Rogerson L, Howell SJ, Landberg G, et al. (2013) Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signaling. Breast Cancer Res 15: R21.
[10]
Zhang XL, Yue PB, Page BD, Li TS, Zhao W, et al. (2012) Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 109: 9623–9628.
[11]
Page C, Huang M, Jin X, Cho K, Lilja J, et al. (2000) Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int J Oncol 17: 23–31.
[12]
Cataldo L, Chen NY, Yuan Q, Li W, Ramamoorthy P, et al. (2000) Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 17: 1179–1264.
[13]
Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97–105.
[14]
Ren XM, Duan L, He Q, Zhang Z, Zhou Y, et al. (2010) Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett 1: 454–459.
[15]
Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548–2556.
[16]
Srivastava K, Kundumani-Sridharan V, Zhang BL, Bajpai AK, Rao GN (2007) 15 (S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires STAT3-dependent expression of VEGF. Cancer Res 67: 4328–4336.
[17]
Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer cell 15: 91–102.
[18]
Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, et al. (2011) Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71: 6601–6610.
[19]
Li R, You S, Hu ZL, Chen ZG, Sica GL, et al. (2013) Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PloS One 8: e74670.
[20]
Garin J, Despeignes J, Billerau M (1964) Present treatment of taeniasis with niclosamide. Lyon Med. 212: 1581–1588.
[21]
Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, et al. (2013) Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12: 2200–2212.
[22]
Jin YL, Lu ZZ, Ding K, Li J, Du X, et al. (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res 70: 2516–2527.
[23]
Wang AM, Ku HH, Liang YC, Chen YC, Hwu YM, et al. (2009) The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem. 106: 682–692.
[24]
Osada T, Chen MY, Yang XY, Spasojevic I, Vandeusen JB, et al. (2011) Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 71: 4172–4182.
[25]
Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, et al. (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4: e7124.
[26]
Pan JX, Ding K, Wang CY (2012) Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 31: 178–184.
[27]
Sack U, Walther W, Scudiero D, Selby M, Kobelt D, et al. (2011) Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 103: 1018–1036.
[28]
Yo YT, Lin YW, Wang YC, Balch C, Huang RL, et al. (2012) Growth Inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther 11: 1703–1712.
[29]
Wang YC, Chao TK, Chang CC, Yo YT, Yu MH, et al. (2013) Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS One 8: e74538.
[30]
Hao H, Liu M, Wu P, Cai L, Tang K, et al. (2011) Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett 309: 85–94.
[31]
Song XJ, Xia Y, Wang NY, Zhang LD, Shi XH, et al. (2013) A novel benzothiazole derivative YLT322 induces apoptosis via the mitochondrial apoptosis pathway in vitro with anti-tumor activity in solid malignancies. PloS One 8: e63900.
[32]
Kortylewski M, Kujawski M, Wang TH, Wei S, Zhang SM, et al. (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314–1321.
[33]
Khan S, Lopez-Dee Z, Kumar R, Ling J (2013) Activation of NFkB is a novel mechanism of pro-survival activity of glucocorticoids in breast cancer cells. Cancer Lett 337: 90–95.
[34]
Zhang T, Li JJ, Dong YM, Zhai D, Lai L, et al. (2012) Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 135: 445–458.
[35]
Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591–602.
[36]
Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res 58: 1486–1493.
[37]
Wang YS, Li D, Shi HS, Wen YJ, Yang L, et al. (2009) Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin Cancer Res 15: 6901–6911.
[38]
Cheng PY, Corzo CA, Luetteke N, Yu B, Nagaraj S, et al. (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235–2249.
[39]
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, et al. (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16: 4583–4594.
[40]
Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425: 851–856.
[41]
Hsieh FC, Cheng G, Lin J (2005) Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Bioph Res Commun 335: 292–299.
[42]
Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000–2008.
[43]
Saunders MM, Seraj MJ, Li ZY, Zhou ZY, Winter CR, et al. (2001) Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res. 61: 1765–1767.
[44]
Chen JS, Huang XH, Wang Q, Chen XL, Fu XH, et al. (2010) FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastas 27: 71–82.
[45]
Xin H, Zhang CY, Herrmann A, Du Y, Figlin R, et al. (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69: 2506–2513.
[46]
Peinado H, Lavotshkin S, Lyden D (2011) The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21: 139–146.
